Barclays raised the firm’s price target on AbbVie to $200 from $187 and keeps an Overweight rating on the shares. The company reported a strong quarter and raised the 2024 guidance, the analyst tells investors in a research note. The firm says AbbVie’s 2025 growth messaging “incrementally de-risks” the over $12 in earnings per share for 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- ABBV Earnings: AbbVie Exceeds Q2 Expectations Driven by Strong Immunology Sales
- AbbVie Reports Second-Quarter 2024 Financial Results
- Options Volatility and Implied Earnings Moves Today, July 25, 2024
- Notable companies reporting before tomorrow’s open
- Frontier Medicines announces milestone payment in AbbVie partnership